About the Editors

Editor-in-Chief 

Stephen J. Freedland, MD, USA

Stephen J. Freedland, MD, is director of the Center for Integrated Research in Cancer and Lifestyle and co-director of the Cancer Genetics and Prevention Program and Associate Director for Faculty Development at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute. He is also a faculty physician in the Division of Urology within the Department of Surgery at Cedars-Sinai. He has served on numerous American Urological Association guideline panels for prostate cancer and co-chaired a prostate cancer guideline panel for the American Society of Clinical Oncology.

Dr. Freedland's clinical area of expertise focuses on urological diseases, particularly benign prostatic hyperplasia and prostate cancer. His approach toward cancer prevention and awareness focuses on treating the whole patient, not just the disease, by combining traditional Western medicine with complementary holistic interventions. His research interests include investigations on urological diseases and the role of diet, lifestyle and obesity in prostate cancer development and progression, as well as prostate cancer among racial groups and risk stratification for men with prostate cancer.

Dr. Freedland has participated in over 400 published studies, and his research has appeared multiple times in The Journal of the American Medical Association, Journal of the National Cancer Institute, Journal of Clinical Oncology, The Journal of Urology, Cancer Prevention Research, Cancer and BJUI, among many others.

In addition to contributing original research, Dr. Freedland is an active reviewer for more than 50 peer-reviewed journals. He sits on the editorial board for Cancer Prevention Research, European Urology, International Journal of Urology, Nature Reviews Urology and BJUI, and serves as editor-in-chief for Prostate Cancer and Prostatic Disease and as a consulting editor for European Urology.

Dr. Freedland earned his medical degree from the University of California, Davis, and continued his training with a residency in Urology at the UCLA Medical Center. He completed his fellowship in urological oncology at the Johns Hopkins Hospital. Before joining Cedars-Sinai, Dr. Freedland was at Duke University School of Medicine, where he specialized in surgical oncology and urologic oncology, and served as an associate professor with tenure in the Division of Urology, Department of Surgery and in the Department of Pathology.

Associate Editor 

Andrew Armstrong

Dr. Armstrong is Associate Professor of Medicine, Surgery, Pharmacology and Cancer Biology and Associate Director of the Duke Cancer Institute Genitourinary Clinical Research Program. He is a medical oncologist and internationally recognized expert in experimental therapeutics and biomarker development in genitourinary cancers, particularly in prostate cancer. He trained at Duke as a biomedical engineer, received his medical degree at the University of Virginia, medicine residency training at the Universtity of Pennsylvania, fellowship and public health clinical investigation training at Johns Hopkins and the Bloomberg School of Public Health, and joined Duke's faculty in 2006. As a clinical and translational investigator, he is focused on experimental therapeutics for patients with advanced genitourinary malignancies, particularly with a focus on prostate cancer and the investigation of biomarkers of response and benefit. He is funded by the US Department of Defense, the Prostate Cancer Foundation and Movember, the NIH, and the American Cancer Society for his work on circulating tumor cell biology and epithelial plasticity. He co-chaired Prostate Cancer Working Group 3 which established guidelines in 2016 for clinical research in advanced prostate cancer, and is a leading member of the NCCN Prostate Cancer panel for national clinical guidelines on the treatment of men with prostate cancer. He has developed a number of experimental agents in prostate and renal cell cancer, including completed or ongoing trials of mTOR inhibitors and PI3 kinase inhibitors, immunomodulatory agents, hormonal therapies such as enzalutamide, and anti-angiogenic agents, and is heavily involved in the leadership of multiple ongoing phase 1-4 treatment and biomarker trials in men with advanced prostate cancer. He has authored over 120 peer reviewed publications as well as numerous chapters, reviews, and abstracts.

Associate Editor 

J. Kellogg Parsons

J. Kellogg Parsons, MD, MHS, is Professor of Surgery in the Department of Urology at the Moores UC San Diego Comprehensive Cancer Center. His research focuses on prostate cancer, BPH, and patient safety. An author of original research papers appearing in JAMA, JAMA Surgery, The New England Journal of Medicine, European Urology, the Journal of Urology, and others, he is a principle investigator for multi-center clinical trials funded by the NIH and the Department of Defense. He is a consulting editor for European Urology; Vice Chair of the NCCN Panel on Prostate Cancer Early Detection; Chair of the GU Surgery Committee of the Alliance for Clinical Trials in Oncology; and has served on several committees for the American Urological Association. Dr. Parsons' clinical practice focuses on prostate cancer, BPH, and bladder cancer. He has been peer-elected to the America's Best Doctors® and San Diego Medical Society Top Doctors lists for several years. Dr. Parsons attended medical school at the University of Pennsylvania and completed residency training and a fellowship in urologic oncology at Johns Hopkins.

Associate Editor 

Henry Woo

Henry Woo is a urological surgeon who is subspecialized in the treatment of prostatic diseases. He is the Professor of Surgery at the Sydney Adventist Hospital Clinical School of the University of Sydney. Additionally, he is the Director of Uro-Oncology and Professor of Robotic Cancer Surgery at the Chris O'Brien LifeHouse cancer hospital. He is a Board Director of the Australian and New Zealand Urogenital and Prostate Cancer trials group (ANZUP) and a Board Director of the Australian Urological Foundation (AUF). He has served in multiple roles with the Urological Society of Australia and New Zealand (USANZ) and is currently on the Executive Committee of the Asian Pacific Prostate Society (APPS). He was the foundation editor of the online CME portal, BJUI Knowledge from 2012-2015. He is on the editorial boards of the journals Prostate Cancer and Prostatic Diseases, European Urology, BJUI, Prostate International and the World Journal of Men's Health. His principal research interests lie with minimally invasive surgical treatments for benign prostatic hyperplasia and clinical trials associated with the treatment of prostate cancer. He is also active in research on the role of social media for medical education and is the coordinator of the highly successful International Urology Journal Club on twitter (#urojc). He is a medical graduate of the University of Sydney and trained in urological surgery through the USANZ administered training programme. He underwent post fellowship training under the mentorship of Professor Christopher Chapple at the Royal Hallamshire Hospital (Sheffield, UK).

Associate Editor 

Jack A Schalken

Jack A Schalken PhD (1959) has an appointment as professor of experimental urology at Radboud University MC, Nijmegen. Dr Schalken was trained as biochemist at the Radboud University Nijmegen, where he also obtained his PhD degree (1987). He did his post doctoral fellowship at Johns Hopkins Hospital (Baltimore, MD). He is director of urological research at the Radboud University Medical Center (1986-now). In 1996 Dr Schalken was (co) appointed as  professor of experimental oncology at the University of Utrecht. Since 2001 he is professor of experimental urology at the Radboud University (Nijmegen). His research has a strong translational component, i.e. conducting life sciences research to accelerate healthcare outcomes, specific themes:

  1. Unravelling the mechanism of (GU) cancer invasion/cadherin switching/EMT
  2. Cancer stem/initiating cells
  3. Targeted therapy in (GU) cancer
  4. Molecular diagnostics of prostate cancer (eg PCA3, SelectMDx)
  5. Combining 1 through 4 to make steps towards precision medicine

Dr Schalken is member of 12 editorial boards of peer reviewed journals and has served- or is serving as board- and or (program)committee member in several professional organizations such as ESUR, SBUR, EAU, ASCO and ESMO. Dr Schalken was  co-founder and CSO of NovioGendix BV, a biomarker company recently acquired by MDxHealth SA and Oncodrone BV, a biopharmaceutical company. Dr Schalken is (co)author on more than 340 peer reviewed publications, 81 book chapters and has edited 10 books/special journal issues. He supervised 34 completed PhD theses. He is inventor on approximately 20 patent applications (some still pending approval).